Figures & data
Figure 1. Patient disposition.
ERA, endothelin receptor antagonist; PAH, pulmonary arterial hypertension; PBS, Pharmaceuticals Benefits Scheme.
![Figure 1. Patient disposition.ERA, endothelin receptor antagonist; PAH, pulmonary arterial hypertension; PBS, Pharmaceuticals Benefits Scheme.](/cms/asset/0927180b-c63b-41df-89ed-afa646a16c04/ijme_a_2328483_f0001_c.jpg)
Table 1. Baseline demographic and clinical characteristics.
Figure 3. Sensitivity analyses for (A) 60% and (B) 70% adherence for all ERA treatments.
CI, confidence interval; ERA, endothelin receptor antagonist; PS, propensity score.
![Figure 3. Sensitivity analyses for (A) 60% and (B) 70% adherence for all ERA treatments.CI, confidence interval; ERA, endothelin receptor antagonist; PS, propensity score.](/cms/asset/f6faabd8-fd2f-4fac-9d53-cceac58c48c0/ijme_a_2328483_f0003_c.jpg)
Figure 4. Time to treatment change (switch or add-on).
Note, time before switching may be impacted by the varying approval dates of the treatments (i.e. 2004 for bosentan, 2009 for ambrisentan, and 2014 for macitentan). NA, not achieved.
![Figure 4. Time to treatment change (switch or add-on).Note, time before switching may be impacted by the varying approval dates of the treatments (i.e. 2004 for bosentan, 2009 for ambrisentan, and 2014 for macitentan). NA, not achieved.](/cms/asset/e2324998-018b-42b5-89d5-e45ed847be0a/ijme_a_2328483_f0004_c.jpg)
Supplemental Material
Download MS Word (295.8 KB)Data availability statement
The de-identified participant data will not be shared.